ACRS logo

ACRS
Aclaris Therapeutics Inc

4,937
Mkt Cap
$632.68M
Volume
250,334.00
52W High
$5.15
52W Low
$1.22
PE Ratio
-8.08
ACRS Fundamentals
Price
$4.54
Prev Close
$4.53
Open
$4.50
50D MA
$4.14
Beta
1.17
Avg. Volume
1.41M
EPS (Annual)
-$0.5297
P/B
4.40
Rev/Employee
$107,205.48
$280.28
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
More News
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim
Guggenheim upgraded Aclaris Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat·15d ago
News Placeholder
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus
Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday, highlighting full top-line results from its phase I-A single-ascending dose (SAD) and multiple-ascending dose (MAD...
MarketBeat·23d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Sells $1,359,000.00 in Stock
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, April 23rd. The...
MarketBeat·23d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Sells 300,000 Shares
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at...
MarketBeat·24d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down - Here's What Happened
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Down - Time to Sell...
MarketBeat·27d ago
News Placeholder
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming
Aclaris Therapeutics (NASDAQ:ACRS) used an H.C. Wainwright inflammatory skin diseases conference fireside chat to outline development plans and differentiation points for its lead biologic candidate...
MarketBeat·1mo ago
News Placeholder
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4%
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,017,767 shares, an increase of 49.4% from the March 15th total of 4,697,214 shares. Based on an average...
MarketBeat·1mo ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·1mo ago
<
1
2
...
>

Latest ACRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.